TECHNICAL NOTES

CorMedin®

Tablets for Dogs

Active Constituents

Each tablet contains 1.25 mg, 2.5 mg or 5 mg pimobendan.

Actions

Pimobendan is a benzimidazole-pyridazinone derivative, and is a non-sympathomimetic, non-glycoside inotropic substance with potent vasodilatative properties.

Pimobendan exerts its stimulatory myocardial effect by a dual mechanism of action: increase in calcium sensitivity of cardiac myofilaments and inhibition of phosphodiesterase (type III). It also exhibits a vasodilating action through an inhibitory action on phosphodiesterase III activity. Following oral administration of pimobendan, the absolute bioavailability of the active principal is 60 – 63%.

The mean plasma protein binding is 93%. The plasma elimination half-life of pimobendan is approximately 30 minutes and the main active metabolite elimination half-life is approximately 2 hours. Almost the entire dose is eliminated via faeces.

Indications

CorMedin Tablets for Dogs are indicated for:

- The treatment of canine congestive heart failure (CHF) originating from dilated cardiomyopathy (DCM) or valvular insufficiency (mitral and / or tricuspid regurgitation).
- The treatment of preclinical DCM in large breeds. When used in cases of preclinical DCM in large breed dogs, pimobendan significantly prolonged the time to the onset of CHF or sudden death, and also resulted in prolongation of the time to death due to all causes.
- Doberman Pinscher dogs with preclinical DCM treated with pimobendan also demonstrated a significant reduction in Left Ventricular Internal Diameter in both systole and diastole (LVIDs/d) in response to therapy.

TECHNICAL NOTES

Contraindications

This product is contraindicated for use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of cardiac output is not recommended for functional or anatomical reasons (e.g. aortic stenosis).

Warnings and Precautions

Use during pregnancy and lactation:

CorMedin tablets should only be administered to pregnant and lactating bitches if the expected therapeutic benefits overweight the potential risk.

In studies with rats and rabbits pimobendan had no effect on fertility and embryotoxic effects only occurred at maternotoxic doses. In rat experiments it has been shown that pimobendan is excreted in milk.

Studies into the effect of pimobendan on the reproductive function of male dogs have not been conducted.

In pharmacological studies, no interaction between the cardiac glycoside ouabain and pimobendan was detected. The pimobendan induced increase in contractility of the heart is attenuated in the presence of the calcium antagonist verapamil and the β-antagonist propranolol.

A moderate positive chronotropic effect and vomiting may occur in rare cases. However, these effects are dose-dependent and can be avoided by reducing the dose in those cases. In rare cases transient diarrhoea, anorexia, or lethargy have been observed.

Dosage and Administration

CorMedin tablets should be administered orally at a dose range of 0.1 – 0.3 mg pimobendan / kg bodyweight twice daily. The ideal dose is 0.25 mg pimobendan / kg bodyweight twice daily administered 12 hours apart. Each dose should be given on an empty stomach, and at least one hour before feeding.

CorMedin tablets may be combined with a diuretic treatment such as furosemide.

An example of the number and tablet size to be administered for a dog within weight bands is given below. However, the veterinarian may choose the dose within the recommended dose range which is appropriate for the patient.

Body-weight (kg)	**Pimobendan dosage 0.2 – 0.6 mg / kg daily divided into two treatments given in the morning and in the evening**					
	No. of tablets per administration					
	Morning			**Evening**		
	1.25 mg	**2.5 mg**	**5 mg**	**1.25 mg**	**2.5 mg**	**5 mg**
5 – 10	1	-	-	1	-	-
>10 – 20	-	1	-	-	1	-
>20 – 40	-	2	-	-	2	-
(select either row)	-	-	1	-	-	1
>40 - 60	-	-	2	-	-	2
>60 - 80	-	-	3	-	-	3
>80	-	-	4	-	-	4

Overdose: In the case of overdosing, symptomatic treatment should be initiated.

TECHNICAL NOTES

First Aid

If poisoning occurs, contact a doctor or Poisons Information Centre on 13 11 26.

GHS Information

For GHS Information see Safety Data Sheet.

Disposal

Dispose of container by wrapping with paper and putting in garbage.

Presentation

Tablets (oblong, white, half scored), 1.25 mg, 2.5 mg, 5 mg: bottles of 84.

Storage

Store below 25ºC (air conditioning).

Poisons Schedule

S4.

Registration Number

APVMA No. 83487 (1.25 mg), 83489 (2.5 mg), 83486 (5 mg).

www.jurox.com.au
Customer Service 1800 023 312